JP2024536791A5 - - Google Patents
Info
- Publication number
- JP2024536791A5 JP2024536791A5 JP2024517107A JP2024517107A JP2024536791A5 JP 2024536791 A5 JP2024536791 A5 JP 2024536791A5 JP 2024517107 A JP2024517107 A JP 2024517107A JP 2024517107 A JP2024517107 A JP 2024517107A JP 2024536791 A5 JP2024536791 A5 JP 2024536791A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- cancer
- fusion protein
- subject
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163245132P | 2021-09-16 | 2021-09-16 | |
| US63/245,132 | 2021-09-16 | ||
| PCT/US2022/043708 WO2023043955A1 (en) | 2021-09-16 | 2022-09-15 | B7-h3 targeting fusion proteins and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024536791A JP2024536791A (ja) | 2024-10-08 |
| JP2024536791A5 true JP2024536791A5 (enExample) | 2025-09-24 |
Family
ID=85603511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024517107A Pending JP2024536791A (ja) | 2021-09-16 | 2022-09-15 | Ｂ７－ｈ３標的指向融合タンパク質及びそれを使用する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250145715A1 (enExample) |
| EP (1) | EP4401776A4 (enExample) |
| JP (1) | JP2024536791A (enExample) |
| KR (1) | KR20240069748A (enExample) |
| CN (1) | CN118119405A (enExample) |
| AU (1) | AU2022347132A1 (enExample) |
| CA (1) | CA3231445A1 (enExample) |
| IL (1) | IL311400A (enExample) |
| WO (1) | WO2023043955A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202547545A (zh) * | 2024-01-26 | 2025-12-16 | 美商馬里亞納腫瘤學公司 | 靶向ｂ７－ｈ３之胜肽及其構築體 |
| CN118894946A (zh) * | 2024-07-24 | 2024-11-05 | 香港大学深圳医院 | 触发因子融合b7h3的原核表达方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10717965B2 (en) * | 2013-01-10 | 2020-07-21 | Gloriana Therapeutics, Inc. | Mammalian cell culture-produced neublastin antibodies |
| US11254744B2 (en) * | 2015-08-07 | 2022-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| CN109562126A (zh) * | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| US12076343B2 (en) * | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
-
2022
- 2022-09-15 KR KR1020247011902A patent/KR20240069748A/ko active Pending
- 2022-09-15 JP JP2024517107A patent/JP2024536791A/ja active Pending
- 2022-09-15 CA CA3231445A patent/CA3231445A1/en active Pending
- 2022-09-15 EP EP22870712.1A patent/EP4401776A4/en active Pending
- 2022-09-15 WO PCT/US2022/043708 patent/WO2023043955A1/en not_active Ceased
- 2022-09-15 US US18/690,991 patent/US20250145715A1/en active Pending
- 2022-09-15 AU AU2022347132A patent/AU2022347132A1/en active Pending
- 2022-09-15 IL IL311400A patent/IL311400A/en unknown
- 2022-09-15 CN CN202280066320.XA patent/CN118119405A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105142663B (zh) | 用于癌症靶向治疗的含有结合白蛋白的精氨酸脱亚胺酶的药物组合物 | |
| TWI840433B (zh) | 新穎合理設計的蛋白質組合物 | |
| JP2010540453A5 (enExample) | ||
| AU2016336451A1 (en) | Therapeutic compounds and methods | |
| JP2024536791A5 (enExample) | ||
| JP2021531265A5 (enExample) | ||
| CN104342444B (zh) | 一种重组trail蛋白及其制备方法和用途 | |
| EP3904381A1 (en) | Antibody fusion protein, preparation method therefor and application thereof | |
| JP2021525549A5 (enExample) | ||
| CN105531284A (zh) | 细胞穿透肽和包含其的缀合物 | |
| CN104311672B (zh) | 一种具有肿瘤细胞靶向性的抑制剂多肽 | |
| CN102993314B (zh) | 一种抗肿瘤融合蛋白及其制备方法和用途 | |
| CN105985447B (zh) | 一种白蛋白结合型肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途 | |
| CN102153655B (zh) | 一种靶向抗肿瘤重组蛋白质及其制备方法 | |
| CN103087199A (zh) | 一种胃癌靶向重组毒素及其制备方法 | |
| CN101139399A (zh) | 重组靶向杀伤白血病细胞的融合蛋白及其制备方法和用途 | |
| CN104592394A (zh) | Fgfr3单链抗体-鱼精蛋白融合蛋白及其应用 | |
| US11952402B2 (en) | Fusion protein containing trail and IgG binding domain and the uses thereof | |
| US11414468B2 (en) | Factor B and C2 protein point mutants, a method for enhancing the activity of anti-cancer antibodies, the pharmaceutical composition and the use of mutants | |
| CN103214580B (zh) | 一种抗Her2免疫细胞因子及其应用 | |
| WO2020181402A1 (zh) | 一种抗肿瘤多肽及其应用 | |
| WO2013053080A1 (zh) | 一种抗肿瘤融合蛋白及其编码基因和应用 | |
| RU2020122291A (ru) | Слитый белок, включающий белок il-2 и белок cd80, и его применение | |
| CN106674352A (zh) | 抗肿瘤蛋白内皮抑素的衍生物及应用 | |
| JP2025542299A (ja) | マクロファージを極性化するための方法 |